Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents.

Hidekazu IshidaMasao TakemuraAtsushi SuetsuguTakafumi NaikiTakuji TanakaTomita EiichiGinette SerreroHidetoshi MatsunamiYasuko YamamotoKuniaki Saito

Published in: Annals of clinical biochemistry (2021)

Sustained high concentrations of serum GP88 in patients treated with direct-acting antiviral agents are correlated with the risk of developing hepatocellular carcinoma.

Keyphrases

sars cov